Do we need new antiarrhythmic compounds in the era of implantable cardiac devices and percutaneous ablation?

Cardiovascular Research

Volumn 68, Issue 3, 2005, Pages 341-343

  Christ, Torsten ^a   Ravens, Ursula ^a,b  

^a DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^b Inst fur Pharmakol und Toxikologie   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; ANTIARRHYTHMIC AGENT; AZIMILIDE; DOFETILIDE; FLECAINIDE; IBUTILIDE; ION CHANNEL; POTASSIUM CHANNEL BLOCKING AGENT; POTASSIUM CHANNEL HERG; PROPAFENONE; TEDISAMIL;

ANTICOAGULANT THERAPY; CARDIOMYOPATHY; DEFIBRILLATOR; DRUG MECHANISM; DRUG SAFETY; DRUG SELECTIVITY; DRUG USE; EDITORIAL; HEART ATRIUM ARRHYTHMIA; HEART PACING; HEART VENTRICLE REMODELING; HEART VENTRICLE TACHYCARDIA; HOSPITAL PATIENT; HUMAN; PRIORITY JOURNAL; RADIOFREQUENCY ABLATION; SELF MEDICATION; SINUS RHYTHM; STROKE; TORSADE DES POINTES;

ANTI-ARRHYTHMIA AGENTS; ARRHYTHMIA; CATHETER ABLATION; COMBINED MODALITY THERAPY; ELECTRIC COUNTERSHOCK; HEART-ASSIST DEVICES; HUMANS; POTASSIUM CHANNEL BLOCKERS;

EID: 27644433455     PISSN: 00086363     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cardiores.2005.09.013     Document Type: Editorial

References (15)

1. The Sicilian gambit: a new approach to the classification of antiarrhythmic drugs based on their actions on arrhythmogenic mechanisms. Task Force of the Working Group on Arrhythmias of the European Society of Cardiology Circulation 84 1991 1831 1851
2. Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) Investigators Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure N Engl J Med 352 2005 225 237
3. A. Mazur, M.E. Anderson, S. Bonney, and D.M. Roden Pause-dependent polymorphic ventricular tachycardia during long-term treatment with dofetilide: a placebo-controlled, implantable cardioverter-defibrillator-based evaluation J Am Coll Cardiol 37 2001 1100 1105
4. I.R. Hanna, and J.J. Langberg The shocking story of azimilide Circulation 110 2004 3624 3626
5. H.J. Wellens Cardiac arrhythmias: the quest for a cure: a historical perspective J Am Coll Cardiol 44 2004 1155 1163
6. AFFIRM Investigators A comparison of rate control and rhythm control in patients with atrial fibrillation. The Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Investigators N Engl J Med 347 2002 1825 1833
7. D.S. Echt, P.R. Liebson, L.B. Mitchell, R.W. Peters, D. Obias-Manno, and A.H. Barker Mortality and morbidity in patients receiving encainide, flecainide, or placebo: the Cardiac Arrhythmia Suppression Trial (CAST) N Engl J Med 324 1991 781 788
8. G. Seebohm Activators of cation channels: potential in treatment of channelopathies Mol Pharmacol 67 2005 585 588
9. 2+ waves in arrhythmogenic Purkinje cells that survive in infarcted canine heart Heart Rhythm 1 2004 218 226
10. J. Reisinger, E. Gatterer, W. Lang, T. Vanicek, G. Eisserer, and T. Bachleitner Flecainide versus ibutilide for immediate cardioversion of atrial fibrillation of recent onset Eur Heart J 15 2004 1318 1324
11. P. Alboni, G.L. Botto, N. Baldi, M. Luzi, V. Russo, and L. Gianfranchi Outpatient treatment of recent-onset atrial fibrillation with the "pill-in-the-pocket" approach N Engl J Med 351 2004 2384 2391
12. D. Dobrev, and U. Ravens Remodeling of cardiomyocyte ion channels in human atrial fibrillation Basic Res Cardiol 98 2003 137 148
13. Kur in controlling action potential shape and contractility in the human atrium: influence of chronic atrial fibrillation Circulation 110 2004 2299 2306
14. G. Nichol, F. McAlister, B. Pham, A. Laupacis, B. Shea, and M. Green Meta-analysis of randomised controlled trials of the effectiveness antiarrhythmic agents at promoting sinus rhythm in patients with atrial fibrillation Heart 87 2002 535 543
15. T. Yamashita, A. Sekiguchi, Y.K. Iwasaki, K. Sagara, S. Hatano, and H. Iinuma Thrombomodulin and tissue factor pathway inhibitor in endocardium of rapidly paced rat atria Circulation 108 2003 2450 2452